޲Ʊ

REVENUE OF LEQEMBI® (PRELIMINARY BASIS)

޲Ʊ., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “޲Ʊ”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).

 

This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). ޲Ʊ’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in ޲Ʊ's financial disclosure scheduled on May 15, 2024.

 

޲Ʊ serves as the lead of lecanemab development and regulatory submissions globally with both ޲Ʊ and Biogen Inc. co-commercializing and co-promoting the product and ޲Ʊ having final decision-making authority.

&Բ;〶

&Բ;〶

Media Inquiries:

Public Relations Department,

޲Ʊ., Ltd.

+81-(0)3-3817-5120

&Բ;〶